Previous Page  3 / 6 Next Page
Information
Show Menu
Previous Page 3 / 6 Next Page
Page Background

Volume 6, Issue 6(Suppl)

J Gastrointest Dig Syst

ISSN:2161-069X JGDS, an open access journal

Page 21

Clinical Gastroenterology 2016

October 03-05, 2016

conference

series

.com

October 03-05, 2016 Toronto, Canada

8

th

International Conference on

Clinical Gastroenterology & Hepatology

Andrew Vaillant, J Gastrointest Dig Syst 2016, 6:6(Suppl)

http://dx.doi.org/10.4172/2161-069X.C1.039

Nucleic acid polymers: Broad spectrum antiviral agents and their development as the backbone of

new antiviral therapies for the treatment of chronic HBV and HBV/HDV infection

N

ucleic Acid Polymers (NAPs) are an emerging antiviral technology with broad spectrum activity in a variety of enveloped

viruses. Through a novel, sequence independent application of oligonucleotide technology, NAPs are able to interfere with

entry and post entry mechanisms in many of the viral infections afflicting humans. The pharmacologic features of NAPs, the

mechanistic basis for their broad spectrum antiviral activity and their unique antiviral properties in HBV and HDV infection

will be discussed as well as their antiviral effects and ability to synergize with immunotherapy to achieve functional control of

infection in completed and ongoing clinical trials in patients with chronic HBV infection and HBV/HDV co-infection.

Biography

Andrew Vaillant is the Inventor of Replicor’s NAP technology and has more than 15 years of experience in viral biology, antiviral drug development and nucleic acid

chemistry. He has authored numerous publications and patents on the development and use of NAPs as agents to treat infectious diseases. He previously held

positions at two Montreal-area biotechnology companies. He was a Post-doctoral fellow at the Montreal Neurological Institute and holds a PhD in Cell Biology from

the University of Ottawa.

availlant@replicor.com

Andrew Vaillant

Replicor Inc., Canada